Literature DB >> 25955298

Let-7a regulates mammosphere formation capacity through Ras/NF-κB and Ras/MAPK/ERK pathway in breast cancer stem cells.

Chongwen Xu1, Xin Sun, Sida Qin, Huangzhen Wang, Zhiwei Zheng, Shaohua Xu, Gang Luo, Peng Liu, Jian Liu, Ning Du, Yunfeng Zhang, Dapeng Liu, Hong Ren.   

Abstract

Breast cancer stem cells (BCSCs) have the greatest potential to maintain tumorigenesis in all subtypes of tumor cells and were regarded as the key drivers of tumor. Recent evidence has demonstrated that BCSCs contributed to a high degree of resistance to therapy. However, how BCSCs self renewal and tumorigenicity are maintained remains obscure. Herein, our study illustrated that overexpression of let-7a reduced cell proliferation and mammosphere formation ability of breast cancer stem cells(BCSCs) in a KRas-dependent manner through different pathways in vitro and in vivo. To be specific, we provided the evidence that let-7a was decreased, and reversely the expression of KRas was increased with moderate expression in early stages (I/II) and high expression in advanced stages (III/IV) in breast cancer specimens. In addition, the negative correlation between let-7a and KRas was clearly observed. In vitro, we found that let-7a inhibited mammosphere-forming efficiency and the mammosphere-size via NF-κB and MAPK/ERK pathway, respectively. The inhibitory effect of let-7a on mammosphere formation efficiency and the size of mammospheres was abolished after the depletion of KRas. On the contrary, enforced expression of KRas rescued the effect of let-7a. In vivo, let-7a inhibited the growth of tumors, whereas the negative effect of let-7a was rescued after overexpressing KRas. Taken together, our findings suggested that let-7a played a tumor suppressive role in a KRas-dependent manner.

Entities:  

Keywords:  BCSCs, breast cancer stem cells; MAPK/ERK; MFE, mammosphere-forming efficiency; NF-κB; breast cancer stem cells, KRas, let-7a; mammosphere formation capacity

Mesh:

Substances:

Year:  2015        PMID: 25955298      PMCID: PMC4615052          DOI: 10.1080/15384101.2015.1030547

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  57 in total

Review 1.  ERK and p38 MAPK-activated protein kinases: a family of protein kinases with diverse biological functions.

Authors:  Philippe P Roux; John Blenis
Journal:  Microbiol Mol Biol Rev       Date:  2004-06       Impact factor: 11.056

2.  Cancer stem cells--perspectives on current status and future directions: AACR Workshop on cancer stem cells.

Authors:  Michael F Clarke; John E Dick; Peter B Dirks; Connie J Eaves; Catriona H M Jamieson; D Leanne Jones; Jane Visvader; Irving L Weissman; Geoffrey M Wahl
Journal:  Cancer Res       Date:  2006-09-21       Impact factor: 12.701

3.  RAS is regulated by the let-7 microRNA family.

Authors:  Steven M Johnson; Helge Grosshans; Jaclyn Shingara; Mike Byrom; Rich Jarvis; Angie Cheng; Emmanuel Labourier; Kristy L Reinert; David Brown; Frank J Slack
Journal:  Cell       Date:  2005-03-11       Impact factor: 41.582

4.  Regulation of let-7 and its target oncogenes (Review).

Authors:  Xirui Wang; Lei Cao; Yingyi Wang; Xiefeng Wang; Ning Liu; Yongping You
Journal:  Oncol Lett       Date:  2012-02-14       Impact factor: 2.967

5.  Prevalence of CD44+/CD24-/low cells in breast cancer may not be associated with clinical outcome but may favor distant metastasis.

Authors:  Benny K Abraham; Peter Fritz; Monika McClellan; Petra Hauptvogel; Maria Athelogou; Hiltrud Brauch
Journal:  Clin Cancer Res       Date:  2005-02-01       Impact factor: 12.531

6.  ErbB receptor tyrosine kinase/NF-κB signaling controls mammosphere formation in human breast cancer.

Authors:  Kunihiko Hinohara; Seiichiro Kobayashi; Hajime Kanauchi; Seiichiro Shimizu; Kotoe Nishioka; Ei-ichi Tsuji; Kei-ichiro Tada; Kazuo Umezawa; Masaki Mori; Toshihisa Ogawa; Jun-ichiro Inoue; Arinobu Tojo; Noriko Gotoh
Journal:  Proc Natl Acad Sci U S A       Date:  2012-04-05       Impact factor: 11.205

7.  Biological and molecular heterogeneity of breast cancers correlates with their cancer stem cell content.

Authors:  Salvatore Pece; Daniela Tosoni; Stefano Confalonieri; Giovanni Mazzarol; Manuela Vecchi; Simona Ronzoni; Loris Bernard; Giuseppe Viale; Pier Giuseppe Pelicci; Pier Paolo Di Fiore
Journal:  Cell       Date:  2010-01-08       Impact factor: 41.582

8.  Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival.

Authors:  Junichi Takamizawa; Hiroyuki Konishi; Kiyoshi Yanagisawa; Shuta Tomida; Hirotaka Osada; Hideki Endoh; Tomoko Harano; Yasushi Yatabe; Masato Nagino; Yuji Nimura; Tetsuya Mitsudomi; Takashi Takahashi
Journal:  Cancer Res       Date:  2004-06-01       Impact factor: 12.701

Review 9.  Cancer stem cell markers in common cancers - therapeutic implications.

Authors:  Thomas Klonisch; Emilia Wiechec; Sabine Hombach-Klonisch; Sudharsana R Ande; Sebastian Wesselborg; Klaus Schulze-Osthoff; Marek Los
Journal:  Trends Mol Med       Date:  2008-09-03       Impact factor: 11.951

Review 10.  Regulation of gene transcription by mitogen-activated protein kinase signaling pathways.

Authors:  Alan J Whitmarsh
Journal:  Biochim Biophys Acta       Date:  2006-11-17
View more
  19 in total

Review 1.  Unraveling the journey of cancer stem cells from origin to metastasis.

Authors:  Rama Krishna Nimmakayala; Surinder K Batra; Moorthy P Ponnusamy
Journal:  Biochim Biophys Acta Rev Cancer       Date:  2018-11-09       Impact factor: 10.680

Review 2.  Breast cancer stem cell: the roles and therapeutic implications.

Authors:  Fang Yang; Jing Xu; Lin Tang; Xiaoxiang Guan
Journal:  Cell Mol Life Sci       Date:  2016-08-16       Impact factor: 9.261

3.  CCAT1 stimulation of the symmetric division of NSCLC stem cells through activation of the Wnt signalling cascade.

Authors:  C Xu; G Xiao; B Zhang; M Wang; J Wang; D Liu; J Zhang; H Ren; X Sun
Journal:  Gene Ther       Date:  2018-01-19       Impact factor: 5.250

4.  LncRNA NEAT1/let-7a-5p axis regulates the cisplatin resistance in nasopharyngeal carcinoma by targeting Rsf-1 and modulating the Ras-MAPK pathway.

Authors:  Fei Liu; Yong Tai; Jiqing Ma
Journal:  Cancer Biol Ther       Date:  2018-04-09       Impact factor: 4.742

5.  Arsenic trioxide inhibits cell growth and motility via up-regulation of let-7a in breast cancer cells.

Authors:  Ying Shi; Tong Cao; Hua Huang; Chaoqun Lian; Ying Yang; Zhiwei Wang; Jia Ma; Jun Xia
Journal:  Cell Cycle       Date:  2017-11-20       Impact factor: 4.534

Review 6.  Multiple Mechanisms of Anti-Cancer Effects Exerted by Astaxanthin.

Authors:  Li Zhang; Handong Wang
Journal:  Mar Drugs       Date:  2015-07-14       Impact factor: 5.118

Review 7.  The NF-κB Pathway and Cancer Stem Cells.

Authors:  Amanda L Rinkenbaugh; Albert S Baldwin
Journal:  Cells       Date:  2016-04-06       Impact factor: 6.600

8.  MiR-208a stimulates the cocktail of SOX2 and β-catenin to inhibit the let-7 induction of self-renewal repression of breast cancer stem cells and formed miR208a/let-7 feedback loop via LIN28 and DICER1.

Authors:  Xin Sun; Shiwen Jiang; Jian Liu; Huangzhen Wang; Yiwen Zhang; Shou-Ching Tang; Jichang Wang; Ning Du; Chongwen Xu; Chenguang Wang; Sida Qin; Jia Zhang; Dapeng Liu; Yunfeng Zhang; Xiaojun Li; Jiansheng Wang; Jun Dong; Xin Wang; Shaohua Xu; Zhen Tao; Fei Xu; Jie Zhou; Tao Wang; Hong Ren
Journal:  Oncotarget       Date:  2015-10-20

Review 9.  Utilizing the Hippo pathway as a therapeutic target for combating endocrine-resistant breast cancer.

Authors:  Qinqin Li; Zhenghuan Rao; Yanlin Wang; Lei Zhang; Jing Chen; Runlan Wan; Alexander Tobias Teichmann
Journal:  Cancer Cell Int       Date:  2021-06-10       Impact factor: 5.722

10.  Short hairpin RNA-mediated gene silencing of ADAM17 inhibits the growth of breast cancer MCF‑7 cells in vitro and in vivo and its mechanism of action.

Authors:  Baoshan Hu; Xiangchao Meng; Yan Zhang; Mohammad Monir Hossain; Lijun Wu; Yuanyuan Zhang; Xiaobing Peng; Xuepeng Zhang
Journal:  Oncol Rep       Date:  2018-01-26       Impact factor: 3.906

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.